ReviewAdvanced healthcare materials2018
Mannose and Mannose-6-Phosphate Receptor-Targeted Drug Delivery Systems and Their Application in Cancer Therapy.
Review in Advanced healthcare materials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 130 citations in OpenAlex.
- Review
- Advances in Research on Autophagy in Steroid-Induced Osteonecrosis of the Femoral Head: Dual Regulation of Its Beneficial and Detrimental Effects.Drug design, development and therapy · 2026Review
- Mannosylated nanocarriers: a precision targeting strategy for tumors and infectious diseases.Frontiers in pharmacology · 2026Review
- Unraveling the Role of Tumor-infiltrating Immune Cells in Modulating Cancer Drug Resistance.Anti-cancer agents in medicinal chemistry · 2026Review
- Ligand Valency and Linker Design Dictate the Efficacy of CI-M6PR-Mediated Targeted Delivery of M6P-siRNA Conjugates.ACS omega · 2025Article
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Triple-synergy bactericidal action: a mannose-decorated bioinspired coating on silver-mesoporous silica for eradicating multidrug-resistantRSC advances · 2025Article
- Multi-omics analyses identify mannose phosphate isomerase-centered hypoxia-induced angiogenesis signature in colorectal cancer.Journal of translational medicine · 2025Article
- A prodrug targeting CIM6P/IGF2R enhances memory in healthy mice and reverses deficits in an Angelman syndrome mouse model.Translational psychiatry · 2025Article
- Hans Paulsen: Contributions to the Investigations of Glycoprotein Biosynthesis.Molecules (Basel, Switzerland) · 2025Review
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses.Communications biology · 2025Article
- Clickable Polymer-Based Coatings for Modulating the Interaction of Metal-Organic Framework Nanocrystals with Living Cells.ACS applied materials & interfaces · 2025Article
- Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy.Asian journal of pharmaceutical sciences · 2025Review
- Metabolic Atlas of Human Eyelid Infiltrative Basal Cell Carcinoma.Investigative ophthalmology & visual science · 2025Article
- Targeted and intelligent nano-drug delivery systems for colorectal cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- Innovative Theranostics Strategies in the Fight Against Lung Cancer.Mini reviews in medicinal chemistry · 2025Review
- Anti-Inflammatory, Cytotoxic, and Genotoxic Effects of Soybean Oligopeptides Conjugated with Mannose.Foods (Basel, Switzerland) · 2024Article
- Polymeric Nanoparticles for Drug Delivery.Chemical reviews · 2024Review
- Targeted photodynamic therapy for breast cancer: the potential of glyconanoparticles.Nanoscale advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In order to overcome the main disadvantages of conventional cancer therapies, which prove to be inadequate because of their lack of selectivity, the development of targeted delivery systems is one of the main focuses in anticancer research. It is repeatedly shown that decorating the surface of nanocarriers with high-affinity targeting ligands, such as peptides or small molecules, is an effective way to selectively deliver therapeutics by enhancing their specific cellular uptake via the binding between a specific receptor and the nanosystems. Nowadays, the need of finding new potential biological targets with a high endocytic efficiency as well as a low tendency to mutate is urgent and, in this context, mannose and mannose-6-phosphate receptors appear promising to target anticancer drugs to cells where their expression is upregulated. Moreover, they open the path to encouraging applications in immune-based and gene therapies as well as in theragnostic purposes. In this work, the potential of mannose- and mannose-6-phosphate-targeted delivery systems in cancer therapy is discussed, emphasizing their broad application both in direct treatments against cancer cells with conventional chemotherapeutics or by gene therapy and also their encouraging capabilities in immunotherapy and diagnostics purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.